Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasm Metastasis 40Lung Neoplasms 34Leukemia, Myeloid, Acute 34Breast Neoplasms 31Multiple Myeloma 25Carcinoma, Non-Small-Cell Lung 25Colorectal Neoplasms 23Prostatic Neoplasms 21Pancreatic Neoplasms 20Melanoma 17Carcinoma, Renal Cell 17Lymphoma 16Urinary Bladder Neoplasms 15Triple Negative Breast Neoplasms 15Ovarian Neoplasms 14Myelodysplastic Syndromes 14Burkitt Lymphoma 12Lymphoma, Large B-Cell, Diffuse 11Squamous Cell Carcinoma of Head and Neck 10Sarcoma 10Leukemia, Lymphocytic, Chronic, B-Cell 10Glioma 10Fallopian Tube Neoplasms 10Mouth Neoplasms 9Endometrial Neoplasms 9Carcinoma, Transitional Cell 9Carcinoma, Hepatocellular 9Carcinoma 9Oropharyngeal Neoplasms 8Laryngeal Neoplasms 8

Interventions

luprolide acetate gel depot 1exemestane 1darolutamide 1X-Rays 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Granulosa cell tumor of the ovary × Specimen Handling × 30 days × Clear all
NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡